AT9283 in children and adolescents with acute leukaemia

• Research type

  Research Study

• Full title

  A Cancer Research UK Phase I trial of AT9283 (a selective inhibitor of aurora kinases) given over 72 hours every 21 days via intravenous infusion in children and adolescents aged 6 months to 18 years with relapsed and refractory acute leukaemia

• IRAS ID

  58252

• Contact name

  Josef Vormoor

• Sponsor organisation

  Cancer Research UK

• Eudract number

  2009-016952-36

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  Children and adolescents aged between six months and eighteen years of age will receive AT9283, a new drug that is hoped will be effective against leukaemia, over a period of 72 hours by continuous intravenous infusion. The dose of AT9283 will beincreased in a controlled fashion as further patients are treated until such time that the side-effects are deemed unacceptable. In this way, a dose will be identified for Phase II evaluation in order to continue further studies with AT9283.

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  10/H0405/75

• Date of REC Opinion

  8 Nov 2010

• REC opinion

  Further Information Favourable Opinion